Record Details     « New Search       Brief Record Full Record MARC Record     Bibliographic Data Control Number 410450 Date and Time of Latest Transaction 20201212061613.AM General Information 201212s |||||||||b ||00||| Cataloging Source DOST-PCHRD Main Entry - Personal Name Yasutan, H   Ndhlovu, L C   Lacuesta, T L   Leano, P S   Telan , E F   Niki , T   Hirashima, M   Dimaano, E M   Hattori, T Title Statement Elevated levels of circulating galectin-9, a novel immune-modulator, in acute dengue virus Infection reflects disease severity Physical Description 18 Summary, Etc. Following a dramatic rise in incidence in recent decades, Dengue virus infection (DENV) is now a significant burden of disease in the tropics and major international public health concern. Currently no treatment or effective vaccine exists. The B-Galactoside-binding lectin, Galectin-9 (Gal-9), functions as pro-apoptotic agent and inducer of pro-inflammatory cytokines from T cells. Here, we sought to evaluate the role of Gal-9 in the pathogenesis of acute DENV in patients presenting with self-limiting dengue fever (DF) and more serious life-threatening dengue hemorrhagic fever (DHF). Blood samples were obtained from 65 patients (mean age: 23?4yrs) hospitalized with DENV from the San Lazaro Hospital, Manila, Philippines in 2010. Plasma Gal-9 was measured by an ELISA method at the critical phase (day4-5) and recovery phase (day7-8) of infection. Our results show that during the critical phase, Gal-9 levels were markedly elevated in DF (1758?1047pg/ml) and DHF(2730?1848pg/ml) compared to uninfected (363?280pg/ml) (p Subject Added Entry - Topical Term DENGUE VIRUS   DISEASE   GALECTIN-9   INFECTION   DENGUE VIRUS   DISEASE   GALECTIN-9   INFECTION           Physical Location           Digital Copy Not Available          Add to Book Cart  |   Download MARC